Ultragenyx Pharmaceutical Inc Revenue Growth Rates (RARE), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ultragenyx Pharmaceutical Inc   (NASDAQ: RARE)
 

RARE's Revenue Growth by Quarter and Year

Ultragenyx Pharmaceutical Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RARE/growth
https://api.csimarket.com/api/v1/companies/RARE/fundamentals
https://api.csimarket.com/api/v1/companies/RARE/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
RARE Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 173.00
2nd Quarter June 214.00
1st Quarter March 136.00
FY 523.00

RAREs Annual Revenue
Ultragenyx Pharmaceutical Inc 's Revenue in the fiscal year 2025 $ 673.00 millions
Ultragenyx Pharmaceutical Inc 's Revenue in the fiscal year 2024 $ 560.23 millions
Ultragenyx Pharmaceutical Inc 's Revenue in the fiscal year 2023 $ 434.25 millions
Ultragenyx Pharmaceutical Inc 's Revenue in the fiscal year 2022 $ 363.33 millions
Ultragenyx Pharmaceutical Inc 's Revenue in the fiscal year 2021 $ 351.41 millions




RARE Revenue third quarter 2026 Y/Y Growth Comment
Ultragenyx Pharmaceutical Inc reported Revenue growth of 8.17% year on year in the third quarter 2026, to $ 173.00 millions, this is lower than Ultragenyx Pharmaceutical Inc 's recent average Revenue rise of 57.61%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue growth. While Ultragenyx Pharmaceutical Inc ' s Revenue increase of 8.17% ranks overall at the positon no. 2016 in the third quarter 2026.


RARE Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 8.17 %
2nd Quarter June 28.53 %
1st Quarter March -2.36 %
FY   -

Financial Statements
Ultragenyx Pharmaceutical Inc 's third quarter 2026 Revenue $ 173.00 millions RARE's Income Statement
Ultragenyx Pharmaceutical Inc 's third quarter 2025 Revenue $ 159.93 millions Quarterly RARE's Income Statement


RARE Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -19.16 %
2nd Quarter June 57.35 %
1st Quarter March -34.39 %
FY (Year on Year)   -


Back to RARE Growth rate Comparisons >> Back to RARE Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #310
Overall #2016

Revenue Y/Y Growth Statistics
High Average Low
174.2 % 57.61 % -6.98 %
(Mar 31 2021)   (Jun 30 2022)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #310
Overall #2016
Revenue Y/Y Growth Statistics
High Average Low
174.2 % 57.61 % -6.98 %
(Mar 31 2021)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ultragenyx Pharmaceutical Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1119.19 % 57.94 % -100 %
(Dec 31 2017)  


RARE's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Ultragenyx Pharmaceutical Inc disclosed fall in Revenue from the second quarter by -19.16% to $ 173.00 millions, from $ 214.00 millions achived in the previous reporting period.

But that's not important problem, as Ultragenyx Pharmaceutical Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Ultragenyx Pharmaceutical Inc 's Revenue growth quarter on quarter, overall rank is 220.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #60
Overall #220
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #60
Overall #220
Revenue Q/Q Growth Statistics
High Average Low
1119.19 % 57.94 % -100 %
(Dec 31 2017)  


RARE's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Ultragenyx Pharmaceutical Inc disclosed fall in Revenue from the second quarter by -19.16% to $ 173.00 millions, from $ 214.00 millions achived in the previous reporting period.

But that's not important problem, as Ultragenyx Pharmaceutical Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Ultragenyx Pharmaceutical Inc 's Revenue growth quarter on quarter, overall rank is 220.


Ultragenyx Pharmaceutical Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 717.21
Y / Y Revenue Growth (TTM) 17.55 %
Year on Year Revenue Growth Overall Ranking # 637
Seqeuential Revenue Change (TTM) 7.09 %
Seq. Revenue Growth (TTM) Overall Ranking # 2275


Cumulative Revenue growth Comment
Although Ultragenyx Pharmaceutical Inc 's Annual Revenue growth year on year were below company's average 56.23% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 17.55% year on year, from 13.38% in Mar 31 2026.

In the Healthcare sector 133 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 399 to 637.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 134
Overall # 637

Revenue TTM Y/Y Growth Statistics
High Average Low
174.2 %
 56.23 %
-6.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 330
S&P 500 # 2275
Cumulative Revenue growth Comment
Although Ultragenyx Pharmaceutical Inc 's Annual Revenue growth year on year were below company's average 56.23% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 17.55% year on year, from 13.38% in Mar 31 2026.

In the Healthcare sector 133 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 399 to 637.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 134
Overall # 637

Revenue TTM Y/Y Growth Statistics
High Average Low
174.2 %
56.23 %
-6.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 330
S&P 500 # 2275




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RARE's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions
Cryoport inc 13.54%$ 13.535 millions
Neuronetics Inc 13.35%$ 13.350 millions
Royalty Pharma Plc13.26%$ 13.263 millions
Evolus Inc 13.23%$ 13.235 millions
Privia Health Group Inc 13.19%$ 13.187 millions
Biocryst Pharmaceuticals Inc 13.11%$ 13.110 millions
U S Physical Therapy Inc12.90%$ 12.898 millions
Maravai Lifesciences Holdings Inc 12.78%$ 12.781 millions
Alphatec Holdings Inc 12.67%$ 12.670 millions
Harmony Biosciences Holdings inc 12.61%$ 12.609 millions
Medicinova Inc 12.35%$ 12.355 millions
Bionano Genomics Inc 12.34%$ 12.339 millions
Viemed Healthcare Inc 12.18%$ 12.180 millions
Ufp Technologies Inc 12.15%$ 12.154 millions
Innovage Holding Corp 12.14%$ 12.135 millions
Vertex Pharmaceuticals Inc11.85%$ 11.845 millions
Sanara Medtech Inc 11.67%$ 11.668 millions
Lemaitre Vascular Inc 11.51%$ 11.508 millions
Pacs Group Inc 11.45%$ 11.454 millions
Ocugen Inc 11.36%$ 11.358 millions
Dexcom Inc 11.26%$ 11.263 millions
Elanco Animal Health Incorporated11.26%$ 11.258 millions
Koru Medical Systems Inc 11.19%$ 11.194 millions


About Ultragenyx Pharmaceutical Inc Revenue Growth Rates (RARE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ultragenyx Pharmaceutical Inc (CIK 1515673).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-445718
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ultragenyx Pharmaceutical Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.